Iris International to Buy AlliedPath for Up to $6M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics firm Iris International announced after the close of the market Tuesday that it has agreed to buy AlliedPath, an early-stage, high-complexity CLIA-certified laboratory, for up to $6 million.

Iris will pay $4.7 million in cash and an earn-out of up to $1.3 million subject to certain sales and earnings targets being reached during the next three years. The deal is expected to close by July 30.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: sequencing technique to uncover plant disease-resistance genes, and more.

In a Science Translational Medicine opinion piece, a Merck executive suggests that universities offer money-back guarantees on their research.

NantKwest's Patrick Soon-Shiong received some $148 million in compensation in 2015.

With sequencing moving toward applications, Illumina CEO Francis deSouza says his company has even more to offer, Fast Company reports.